The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells

被引：14

作者：

Freddie, CT ^{[1
]}

Larsen, SS ^{[1
]}

Bartholomæussen, M ^{[1
]}

Lykkesfeldt, AE ^{[1
]}

机构：

[1] Danish Canc Soc, Inst Canc Biol, Dept Tumor Endocrinol, DK-2100 Copenhagen O, Denmark

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2004年 / 219卷 / 1-2期

关键词：

breast cancer; Arzoxifene; LY353381; LY335562; growth inhibition; gene expression;

D O I：

10.1016/j.mce.2004.02.003

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The benzothiophene arzoxifene is a new 3rd generation selective estrogen receptor (ER) modulator (SERM). We have investigated the effect of arzoxifene on growth and gene expression in the estrogen receptor a (ERalpha) positive human breast cancercell line MCF-7. Arzoxifene inhibits cell growth as effectively as the antiestrogen tamoxifen. Northern analysis revealed that arzoxifene exerts a statistically significant inhibition of pS2 and progesterone receptor B mRNA expression. Significant agonistic effect was observed on the antitrypsin mRNA expression. In contrast to estradiol and tamoxifen, arzoxifene does not upregulate cathepsin D mRNA and protein expression. The metabolite of arzoxifene (ARZm) is a more potent growth inhibitor of MCF-7 cells than arzoxifene. A tamoxifen resistant MCF-7 subline displayed a significant dose-dependent growth inhibition to ARZm, whereas an ICI 182,780 resistant cell line only responded to high concentration. Our results indicate that arzoxifene and especially ARZm are efficient growth inhibitors of ER positive human breast cancer cells, including tamoxifen resistant cells. Moreover, arzoxifene displays less estrogen agonistic effects in MCF-7 cells than tamoxifen. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：27 / 36

页数：10

共 52 条

[21] CONSTRUCTION OF CELL-LINES THAT EXPRESS HIGH-LEVELS OF THE HUMAN ESTROGEN-RECEPTOR AND ARE KILLED BY ESTROGENS [J].

KUSHNER, PJ ;

HORT, E ;

SHINE, J ;

BAXTER, JD ;

GREENE, GL .

MOLECULAR ENDOCRINOLOGY, 1990, 4 (10) :1465-1473

[22]

Larsen SS, 1997, INT J CANCER, V72, P1129, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1129::AID-IJC31>3.0.CO

[23]

2-X

[24] Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family [J].

Larsen, SS ;

Egeblad, M ;

Jäättelä, M ;

Lykkesfeldt, AE .

BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (01) :41-56

[25] Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells [J].

Larsen, SS ;

Heiberg, I ;

Lykkesfeldt, AE .

BRITISH JOURNAL OF CANCER, 2001, 84 (05) :686-690

[26]

Levenson AS, 1997, CANCER RES, V57, P3071

[27] Selective oestrogen receptor modulation: Molecular pharmacology for the millennium (Reprinted from Eur J Cancer, vol 35, pg 1974-1985, 1999) [J].

Levenson, AS ;

Jordan, VC .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (14) :1974-1985

[28] Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy [J].

Lien, EA ;

Lonning, PE .

CANCER TREATMENT REVIEWS, 2000, 26 (03) :205-227

[29]

LYKKESFELDT AE, 1994, CANCER RES, V54, P1587

[30] HUMAN BREAST-CANCER CELL-LINES RESISTANT TO PURE ANTIESTROGENS ARE SENSITIVE TO TAMOXIFEN TREATMENT [J].

LYKKESFELDT, AE ;

LARSEN, SS ;

BRIAND, P .

INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (04) :529-534

← 1 2 3 4 5 6 →